Class Action & Mass Torts

Compare 9 Earlier Cases of PML in MS Patients After Ocrevus Treatments: Those Involved Earlier Tysabri and/or Gilenya Use   (Posted by Tom Lamb at Drug Injury Watch)   Pharmaceutical company Genentech knew about the first monotherapy Ocrevus PML case no later than October 2019, but important details about the subject patient and its ramifications in terms of Ocrevus drug safety just came to light in March 2021. The reasons for this delay in…
At Class Certification Stage, Non-Expert Evidence Must Be Reliable, but Not Necessarily Admissible: As the Supreme Court explained 40 years ago in General Telephone Co. of Southwest v. Falcon, 457 U.S. 147, 161 (1982), district courts must undertake a “rigorous analysis” to ensure that the requirements for class certification under Rule 23 have been satisfied. This analysis may require the court to “probe behind the pleadings,” while at other times, “the issues are plain enough…